Since its inception in 2015, GenomeMe has been developing and commercializing novel IVD tools for the detection, characterization and prognosis of cancer in order to make precision medicine more accessible.
Despite that, GenomeMe has also a broad catalog for qualified RUO antibodies of a high quality and low competition in the market: anti IDH1 R132H, anti PD-L1 and anti p-63.
Anti IDH1 R132H
For further information, refer to http://www.genomeme.ca/molecular-pathology/IDH1-R132H.html o write an e-mail to firstname.lastname@example.org. We will be happy to help you!